Use of inhibitors of cyclin-dependent kinase 4/6 (CDK4/6) in mature patients

Title: “Use of inhibitors of cyclin-dependent kinase 4/6 (CDK4/6) in mature patients exhibiting HER2-negative ER-positive breast cancer.”

Authors: Nienke De Glas, Gabor Liposits, Alistair Ring, Enrique Soto-Perez-de-Celis, Ines B. Menjak, Kah Poh Loh, and Jessica L. Krok- Schoen.

Source: Sage Journals

Date of Article: November 20, 2018

            The article above explores the application of inhibitors of cyclin-dependent kinase in treating breast cancer among adult patients exhibiting an ER-positive HER2-negative type of breast tumor (Battisti et al. 1). Age is one of the known risk factors relating to breast cancer, and there is an expectation of the element to increase such risk shortly. The researchers also claim that breast cancer is a common cancer diagnosis in women (Battisti et al. 1). The idea of introducing the new cyclin-dependent kinase inhibitors with the identity of CDK4/6 would be a step forward in the treatment of breast cancer as the journal explains. The researchers demonstrate how adult women aged 60 years and above fall under the majority of breast cancer patients in the entire world. Nevertheless, there is a challenge in determining the specific dosing, the benefit of the inhibitors, and their tolerability. Because of this, clinical trials cannot involve older patients and clinicians have to do their research on the younger individuals to make decisions on how older patients can get their dosage. The journal proposes potential approaches that can help in making informed decisions based on the reactions of older cancer patients to CDK 4/6 inhibitors (Battisti et al. 4). Lastly, the journal claims that some clinical trials are in session right now to evaluate the use of CDK 4/6 inhibitors to treat breast cancer.

                                   Work Cited

Battisti, N De Glas et al. et al. “Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.” Sage Journals (2018).